Our Team
Dermott O’Callaghan
Dermott O’Callaghan, CSO, has 20 years experience in the pharmaceutical industry. His focus has been on early drug discovery in neuroscience with an emphasis on ion channels. He has in-depth experience of numerous drug discovery approaches and technologies ranging from high-throughput screening to pre-clinical candidate selection. His approach is based on embracing the emerging outward facing drug discovery business models to ensure clients are best placed to capitalise on pre-competition interactions, cloud based open-access data sharing, out-sourced experimental work and new technological advancement.
Andy McElroy
Andy McElroy, Acting CEO, has 40 years experience in the pharmaceutical industry. For many years a medicinal chemist and project manager at Pfizer with leadership roles in the pain therapeutic area. He oversaw collaborative work to progress a range of therapeutic projects within TRN and continues to play a role to ensure the effective transfer of these projects to Anocis.
Gunnar Staaf
Gunnar Staaf, MBA has over 30 years’ experience in the pharmaceutical industry in commercial and general management roles across Big Pharma, Biotech and contract research organisations. He executed a management buyout of Avantium Pharma, implemented a turnaround plan and within 5 years sold the business to private equity and assisted in a buy and build strategy to create Ardena.
Gunnar now works as a consultant assisting biotechs in commercial strategy and tactics including fund raising, market analysis and competitive landscape, value proposition and target product profile; key opinion leader programme and market access & pricing.